Treatment with an experimental peanut protein patch can help young children safely build tolerance to peanuts, a new study says. More than 70% of children treated with the Viaskin Peanut Patch could ...

Please provide your email address to receive an email when new articles are posted on . More children treated with the Viaskin Peanut patch vs. placebo were classified as responders at 12 months. DBV ...

・VIASKIN patch is designed to introduce microgram amounts of an allergen like peanuts to the immune system through intact skin to induce tolerance. ・The company now plans to submit an application to ...

Please provide your email address to receive an email when new articles are posted on . At month 12, 46.6% of children using the Viaskin Peanut patch were treatment responders vs. 14.8% of children ...

DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 ...